Carlos Martin brings more than 20 years of leadership experience across global biopharmaceutical markets, with a proven record of building commercial organizations, launching transformative therapies, and strengthening pipeline valuation in highly innovative areas such as gene therapy, radiopharma, oncology, cardiology, and rare diseases.

Carlos Martin most recently served as Chief Commercial Officer at Rocket Pharma, where he oversaw the company’s transition from a clinical-stage biotech to a commercial-ready organization in gene therapies. There, he developed the company’s U.S., EU, and Japan commercialization strategies and go-to-market models including infrastructure and secured pre-launch payer agreements – all designed to accelerate market entry while bolstering investor confidence and company value. Earlier in his career, Martin held senior leadership roles at Novartis Pharmaceuticals. At Advanced Accelerator Applications (a Novartis company), he established the radiopharma commercial business in the U.S. At Novartis Oncology, he managed a $1B portfolio in the U.S. market. Additionally, he was Novartis Oncology country head in Chile where he built a new business unit.